Intratumoral peptide injection enhances tumor cell antigenicity recognized by cytotoxic T lymphocytes: a potential option for improvement in antigen-specific cancer immunotherapy
Daisuke Nobuoka(Fukuyama City Hospital), Tetsuya Nakatsura(Unknown), Toshiaki Yoshikawa(Aichi Cancer Center), Noriko Sakemura(National Cancer Center Hospital East), Kazutaka Horie(Tottori University), Toshiyoshi Fujiwara(Okayama University), Manami Shimomura(National Cancer Center Hospital East), Shiro Suzuki(National Cancer Center Hospital East), Takahito Yagi(Okayama University), Hiroshi Sadamori(Okayama University), Mari Takahashi(Chiba Cancer Center), Munehide Nakatsugawa(Tokyo Medical University Hachioji Medical Center), Tatsuaki Iwama(National Cancer Center Hospital East)
Cited by 48
Related Papers
Phase I Trial of a Glypican-3–Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival
|Clinical Cancer Research|2012|304
CSF1/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma Microenvironment
|Molecular Cancer Therapeutics|2021|258
Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients
|OncoImmunology|2016|178